Clinical Trials Logo

Age-Related Macular Degeneration clinical trials

View clinical trials related to Age-Related Macular Degeneration.

Filter by:
  • Recruiting  
  • « Prev · Page 10

NCT ID: NCT01023971 Recruiting - Clinical trials for Age Related Macular Degeneration

Macular Function During Anti-VEGF Treatment

MAFAT
Start date: January 2009
Phase: N/A
Study type: Observational

The purpose of this study is to determine the changes in macular function during anti-VEGF treatment for neovascular age-related macular degeneration.

NCT ID: NCT00788177 Recruiting - Clinical trials for Age-related Macular Degeneration

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

Start date: November 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular (exudative) age-related macular degeneration (AMD) when the first dose is administered to the submacular space instead of vitreous body in cases when previous state-of-the-art treatment for the AMD was deemed ineffective.

NCT ID: NCT00710229 Recruiting - Clinical trials for Age Related Macular Degeneration

Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration

MANTA
Start date: July 2008
Phase: Phase 3
Study type: Interventional

Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.

NCT ID: NCT00568191 Recruiting - Clinical trials for Age-Related Macular Degeneration

Stratus Versus Cirrus OCT in AMD

Start date: October 2007
Phase: N/A
Study type: Observational

The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected

NCT ID: NCT00455871 Recruiting - Clinical trials for Age-Related Macular Degeneration

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Start date: April 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the benefits, if any, of combination therapy with Lucentis plus reduced fluence photodynamic therapy with Visudyne.